Here are four things to know about the transaction and the company’s stock:
• The shares were sold at an average price of $16.46, for a total value of $196,828.
• Following the transaction, Mr. Pierce now directly owns 28,161 shares of the company’s stock, valued at approximately $463,530.
• The company has an average rating of “buy” and an average target price of $15.63.
• Boston Scientific has a 52-week low of $11.10 and a 52-week high of $16.71.
More articles on GI/endoscopy:
APIC, SHEA address infections linked to duodenscopes
Wisconsin Economic Development Corp. grants Exact Sciences $9M incentive to create 750 jobs
Capsule endoscopy company Check-Cap closes IPO, simultaneous private placement
